About this event
Are you waiting weeks for your GPCRs to express, only to watch them aggregate or lose activity during harsh detergent "scouting"? Despite being some of the most valuable drug targets in the industry, GPCRs make up less than 1% of solved structures in the PDB due to these severe production bottlenecks. The problem isn't your downstream structural biology tech—it's getting stable, active protein in the first place.
Hosted by
oby has 19 years experience in product development for disruptive NGS and Epigenetics-tools companies such as Solexa, Illumina and PacBio. At Nuclera he leads the Reagents team developing cutting-edge CFPS and detection workflows. Toby is the tallest member of the Nuclera team and has a love of Marmite and all things Scottish.
Nuclera empowers researchers to accelerate discovery with rapid, in-house access to high-quality functional proteins.
